Users Online: 176 | Home Print this page Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
EDITORIAL
Year : 2015  |  Volume : 5  |  Issue : 4  |  Page : 179-181

An overview of viral and nonviral delivery systems for microRNA


Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, Fort Wayne, IN 46845, USA

Date of Web Publication20-Oct-2015

Correspondence Address:
Dr. Ningning Yang
School of Pharmacy, Erie College of Osteopathic Medicine - Bradenton, 5000 Lakewood Ranch Blvd, Bradenton, FL 34211
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-973X.167646

Rights and Permissions

How to cite this article:
Yang N. An overview of viral and nonviral delivery systems for microRNA. Int J Pharma Investig 2015;5:179-81

How to cite this URL:
Yang N. An overview of viral and nonviral delivery systems for microRNA. Int J Pharma Investig [serial online] 2015 [cited 2018 Jan 17];5:179-81. Available from: http://www.jpionline.org/text.asp?2015/5/4/179/167646

MicroRNAs (miRNAs) are small endogenous noncoding RNAs that direct posttranscriptional regulation of gene expression. Mature miRNAs function as components of RNA-induced silencing complex and interact directly with the 3'-untranslated region of the target mRNA. The target mRNA is then cleaved when the full complementarity of miRNA-mRNA is achieved. For partial complementarity, the translation of the target mRNA is repressed. It has been estimated that about one-third of human genes are regulated by miRNAs. [1] Deregulation of miRNAs has been found in many diseases including cancer, neurologic disease, metabolic disorders, and cardiovascular disease.

Due to the important function of miRNAs, miRNA therapy has attracted significant attention. miRNA therapy could be categorized into two mechanisms, according to deregulation status of the target mRNA: miRNA replacement therapy that restores the miRNA expression by transduction of exogenous miRNA, and miRNA inhibition therapy that inhibits the miRNA expression by designing anti-miRNA oligonucleotides known as antagomirs. [2],[3] Currently, both viral and nonviral miRNA delivery systems are used, and there are advantages and disadvantages for each approach.

Viral-based systems usually use retroviruses, lentiviruses, and adenoviruses or adeno-associated viruses (AVV) as delivery vectors. [4] These viral vectors are modified in some specific genomic area so that they are unable to replicate, and their safety are increased. The advantage of this delivery system was to provide high transfection or infection efficiency, and a high level of constant expression of miRNAs or antagomirs.

Retroviral vectors are frequently employed to deliver miRNAs into somatic and germline cells. Retroviruses belong to RNA virus family with a genome size of about 7-11 KB. [5] The retroviral genes are removed in the constructed vectors so that space up to 8 KB is made for foreign genetic sequences. Since, the genetic materials carried by the retroviral vectors are integrated into host cell genomic DNAs during the mitotic phase of cell cycle; these vectors are utilized for infecting dividing cells only. Integration of exogenous sequence into host genome enables the stable expression of miRNA. The miRNA expression might be increased greatly by retroviral infection. For example, miR-138 was induced about more than 1,000-fold in mouse embryonic fibroblasts in order to enhance the production of pluripotent stem cells. [6] The miRNA inhibition therapy is also very efficient in the retroviral system. The miR-205 was almost completely repressed in the skin stem cells. [7]

Lentiviruses are a subgroup of retroviruses, which integrate foreign genetic material into the host genome. Similar to retroviral vectors, lentiviral vectors are able to transfer about 8 KB genetic sequences into host cells. In contrast to retroviruses, lentiviruses can infect both dividing and nondividing cells due to their pathogenic characteristics. [8] Therefore, lentiviral vectors are frequently employed to infect postmitotic and terminal differentiated cells to treat neurologic disorders. The lentiviral system produces high transfection efficiency and long-term stable expression of introduced miRNAs. A study found that miR-143 was increased about 2,500-fold in corneal epithelial progenitor cells. [9]

Adenoviruses are double-stranded DNA viruses and contain more than 100 serotypes. Compared to retroviral vectors, adenoviral systems can transfer up to 38 KB foreign DNA, but are unable to integrate the exogenous sequences into host genomic DNA. In contrast to adenoviruses, AAVs are more frequently utilized in miRNA gene delivery. AAVs are single-stranded DNA viruses, which consist of 12 primate serotypes (AAV1-AAV12). AAV vectors could only accommodate up to 4.8 KB exogenous genetic material, which limits its utilization in large gene delivery. However, AAV vectors are favorable in transferring miRNAs due to the small size of miRNA genes. [10] Similar to lentiviruses, adenoviruses, and AAVs can transfect both dividing and nondividing cells. The miR-375 was increased about 17-fold in alveolar epithelial cells using an adenoviral vector. [11] To induce cardiac regeneration, miR-590 and miR-199a were delivered into neonatal mouse heart by an rAAV9 vector. It was found that miR-590 was induced about 240-fold, and miR-199a was increased 3.5-fold compared to the empty rAAV9 vectors. [12]

Although, the viral vectors are replication-deficient, there are some problems that restrict their usages such as toxicity due to the production of toxin, immunogenicity that induce inflammatory response and tissue degeneration, and mutations caused by the inserted sequence. To avoid these limitations, nonviral delivery systems are widely used.

In contrast to viral delivery systems, nonviral systems are much less toxic, immunogenic, and no limitation of the size on the transferred DNA, but lower transfection efficiency. Effective nonviral delivery systems should transport the exogenous miRNAs or miRNA-expressing vectors, and protect these sequences from cellular nuclease-mediated degradation nonviral delivery systems consist of physical approaches and chemical approaches. Physical approaches exert external forces to make the cell membrane transient permeable for the gene delivery, which include gene gun, electroporation, hydrodynamic, ultrasound, and laser-based energy. Physical methods might damage the cell integrity and cause high apoptotic rate, and are hard to prevent nuclease cleavage. Physical approaches are usually applied in vitro studies and seldom used in the miRNA delivery. [4] Chemical methods consist of lipid-based, polymer-based, and inorganic carriers. [3],[13]

Lipid-based approaches utilize the lipid/nucleic acid complexes, named lipoplexes or liposome as delivery carriers. Liposomes are composed of the membrane-like surface, and nucleic acids encapsulated inside. There are three types of liposomes based on the charges: Cationic, anionic, or neutral. Cationic lipoplexes are most commonly used in nonviral delivery systems due to their unique characteristics including ease of production, high affinity with the cell membrane, nonpathogenic, and nonimmunogenic response. Systemic delivery of miR-29b using cationic lipoplex (DOTMA: Cholesterol: TPGS) into nonsmall cell lung cancer cells increased the expression of miR-29b by 5-fold and decreased the tumor growth rate by about 60%. [14] There are many commercially available cationic lipoplex for miRNA delivery, which have been reported to achieve favorable results, such as Lipofectamine ® RNAi-MAX (Invitrogen), [15] SilentFect™ (Bio-Rad), [16] DharmaFECT ® (Dharmacon), [17] and SiPORT™ (Invitrogen). [18]

The most critical disadvantage of liposome delivery system is the short half-lives (several hours) of the nanoparticles in sera due to nonspecific binding to serum proteins. To avoid the instability caused by the interaction of cationic lipids with serum proteins, anionic and neutral liposomes are sometimes used in miRNA delivery, such as miR-29b delivery in acute myeloid leukemia by anionic lipoplexes, [19] and miR-34a transfer in lymphoma through neutral lipids. [20] Conjugation of the lipids with hydrophilic and flexible polyethylene glycol (PEG) could greatly increase their stability and result in long half-lives (up to 72 h in sera). [21] Pramanik et al. constructed lipid nanoparticle by using DOTAP: Cholesterol: DSPE-PEG-OMe at a 1:1:0.2 ratio to deliver miR-143/145 cluster and miR-34a into pancreatic cancer xenograft mice and found increased accumulation of nanoparticles in tumor tissues and decreased tumor size. [22]

Polymer-based approaches utilize polyethylenimine (PEI), poly (lactide-co-glycolide) (PLGA), poly (amidoamine) (PAMAMs) dendrimers, or cell-penetrating peptide (CPP) as delivery carriers. Compared to high molecular weight PEIs and low molecular weight PEIs show lower levels of damage to cell membranes and less cytotoxic to cells. A study used low molecular weight PEIs to deliver miR-33a mimics and miR-145 into colon cancer xenograft mice, resulting in decreased tumor growth and increased cell death. [23] However, the transfection efficiency is really low and PEIs are poorly biodegradable. PLGA is Food and Drug Administration-approved biodegradable copolyester for drug delivery and used in some miRNA therapy studies like delivery anti-miRNAs. [24] The hydrophobic nature of PLGA decreases the miRNA delivery effectiveness. PAMAMs are positively charged polymers and have high transfection efficiency compared to other polymers. PAMAM dendrimer - anti-miR-21 complexes decreased the growth of glioblastoma cells. [25] The major disadvantage of PAMAM dendrimers is the accumulation of the polymers in the liver. [26] Besides these synthetic polymers discussed above, natural derived polymers like CPPs are used for miRNA carriers. For example, an arginine-rich CPP from natural protamine effectively transferred miR-29b into osteogenic stem cells. [27] In contrast to synthetic polymers, CPPs are less toxic but prone to be degraded in sera.

In contrast to lipids and polymers, few studies utilize inorganic materials as miRNA gene delivery. Current inorganic miRNA vectors include gold nanoparticles (AuNPs), Fe 3 O 4 -based nanoparticles, [28] and silica-based nanoparticles [29] among which GNPs are most frequently used. AuNPs have been reported to successfully deliver miR-130b [30] and anti-miR29b [31] into tumor cells. The inorganic carriers have high stability in vivo and are free of microbial attack. However, the interactions between the carriers and nucleic acids are weak. To solve this problem, inorganic and organic hybrid materials are tried. For example, AuNP 10 was conjugated with PEG 0.5 to deliver miR-1 into cancer cells and showed higher transfection efficiency, lower toxicity, and longer half-lives compared to lipofection. [32]

Viral and nonviral miRNA delivery systems have both advantages and disadvantages: Viral vectors produce higher transfection efficiency but are more toxic and immunogenic, whereas nonviral carriers have lower delivery efficiency but are much safer. Therefore, effective and safe miRNA delivery systems are in urgent need. The design of future delivery systems should combine the advantages of both systems to employ more miRNA therapies from bench to bedside.

 
  References Top

1.
Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev 2015;81:62-74.  Back to cited text no. 1
    
2.
Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12:329-40.  Back to cited text no. 2
    
3.
Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev 2015;81:142-60.  Back to cited text no. 3
    
4.
Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012;1:27.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.
Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007;117:2083-6.  Back to cited text no. 5
    
6.
Ye D, Wang G, Liu Y, Huang W, Wu M, Zhu S, et al. miR-138 promotes induced pluripotent stem cell generation through the regulation of the p53 signaling. Stem Cells 2012;30:1645-54.  Back to cited text no. 6
    
7.
Wang D, Zhang Z, O′Loughlin E, Wang L, Fan X, Lai EC, et al. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI(3)K pathway. Nat Cell Biol 2013;15:1153-63.  Back to cited text no. 7
    
8.
Escors D, Breckpot K. Lentiviral vectors in gene therapy: Their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010;58:107-19.  Back to cited text no. 8
    
9.
Lee SK, Teng Y, Wong HK, Ng TK, Huang L, Lei P, et al. MicroRNA-145 regulates human corneal epithelial differentiation. PLoS One 2011;6:e21249.  Back to cited text no. 9
    
10.
Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008;16:1189-99.  Back to cited text no. 10
    
11.
Wang Y, Huang C, Reddy Chintagari N, Bhaskaran M, Weng T, Guo Y, et al. miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/ß-catenin pathway. Nucleic Acids Res 2013;41:3833-44.  Back to cited text no. 11
    
12.
Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, ZacchignaS, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012;492:376-81.  Back to cited text no. 12
    
13.
Yang N. Nonviral gene delivery system. Int J Pharm Investig 2012;2:97-8.  Back to cited text no. 13
    
14.
Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, et al. Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids 2013;2:e84.  Back to cited text no. 14
    
15.
Hara ES, Ono M, Eguchi T, Kubota S, Pham HT, Sonoyama W, et al. miRNA-720 controls stem cell phenotype, proliferation and differentiation of human dental pulp cells. PLoS One 2013;8:e83545.  Back to cited text no. 15
    
16.
Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol 2009;16:365-71.  Back to cited text no. 16
    
17.
Sundaram GM, Common JE, Gopal FE, Srikanta S, Lakshman K, Lunny DP, et al. See-saw expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature 2013;495:103-6.  Back to cited text no. 17
    
18.
Sluijter JP, van Mil A, van Vliet P, Metz CH, Liu J, Doevendans PA, et al. MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler Thromb Vasc Biol 2010;30:859-68.  Back to cited text no. 18
    
19.
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 2013;19:2355-67.  Back to cited text no. 19
    
20.
Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012;26:2421-4.  Back to cited text no. 20
    
21.
Bikram M, Lee M, Chang CW, Janát-Amsbury MM, Kern SE, Kim SW. Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: Degradation profiles and evidence of dysopsonization. J Control Release 2005;103:221-33.  Back to cited text no. 21
    
22.
Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011;10:1470-80.  Back to cited text no. 22
    
23.
Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71:5214-24.  Back to cited text no. 23
    
24.
Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm 2012;9:1481-8.  Back to cited text no. 24
    
25.
Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010;10:27.  Back to cited text no. 25
    
26.
Jiang YY, Tang GT, Zhang LH, Kong SY, Zhu SJ, Pei YY. PEGylated PAMAM dendrimers as a potential drug delivery carrier: In vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J Drug Target 2010;18:389-403.  Back to cited text no. 26
    
27.
Suh JS, Lee JY, Choi YS, Chung CP, Park YJ. Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation. Biomaterials 2013;34:4347-59.  Back to cited text no. 27
    
28.
Schade A, Delyagina E, Scharfenberg D, Skorska A, Lux C, David R, et al. Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles. Int J Mol Sci 2013;14:10710-26.  Back to cited text no. 28
    
29.
Bitar A, Ahmad NM, Fessi H, Elaissari A. Silica-based nanoparticles for biomedical applications. Drug Discov Today 2012;17:1147-54.  Back to cited text no. 29
    
30.
Crew E, Tessel MA, Rahman S, Razzak-Jaffar A, Mott D, Kamundi M, et al. MicroRNA conjugated gold nanoparticles and cell transfection. Anal Chem 2012;84:26-9.  Back to cited text no. 30
    
31.
Kim JH, Yeom JH, Ko JJ, Han MS, Lee K, Na SY, et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. J Biotechnol 2011;155:287-92.  Back to cited text no. 31
    
32.
Ghosh R, Singh LC, Shohet JM, Gunaratne PH. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 2013;34:807-16.  Back to cited text no. 32
    



This article has been cited by
1 Insights into the key roles of epigenetics in matrix macromolecules-associated wound healing
Zoi Piperigkou,Martin Götte,Achilleas D. Theocharis,Nikos K. Karamanos
Advanced Drug Delivery Reviews. 2017;
[Pubmed] | [DOI]
2 MicroRNA as Therapeutic Targets for Chronic Wound Healing
Eoghan J. Mulholland,Nicholas Dunne,Helen O. McCarthy
Molecular Therapy - Nucleic Acids. 2017; 8: 46
[Pubmed] | [DOI]
3 Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery
Melissa Berman,George Mattheolabakis,Megha Suresh,Mansoor Amiji
Expert Opinion on Drug Delivery. 2016; : 1
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed1099    
    Printed48    
    Emailed0    
    PDF Downloaded5440    
    Comments [Add]    
    Cited by others 3    

Recommend this journal